Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kelly Lucas

Podiatrist, Foot & Ankle Surgery Franklin Square, NY Doctor of Podiatric Medicine

NPI 1134563265 CMS profile 1401817

925 Hempstead Tpke, Ste 110, Franklin Square, NY 11010

Open in the dashboard

General payments

$9,755

127 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kelly Lucas of Franklin Square, NY is reported in the CMS Open Payments database as having received $9,755 across 127 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 82nd percentile of Podiatrist, Foot & Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,489 14
2024 General $387 5
2023 General $1,601 16
2022 General $888 15
2021 General $1,275 23
2020 General $264 7
2019 General $3,851 47

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kelly Lucas
  • Podiatrist, Foot & Ankle Surgery median
  • Middle half of Podiatrist, Foot & Ankle Surgery
  • National median

In program year 2025, general payments to Kelly Lucas were reported at $1,489. Among 6,994 Podiatrist, Foot & Ankle Surgery profiles paid that year, the median was $424 and the middle half received between $139 and $1,306.

Show as a table
Year Kelly Lucas Podiatrist, Foot & Ankle Surgery median Middle half National median
2019 $3,851 $389 $118–$1,406 $163
2020 $264 $191 $62–$691 $114
2021 $1,275 $329 $104–$1,341 $132
2022 $888 $419 $125–$1,611 $149
2023 $1,601 $377 $128–$1,164 $160
2024 $387 $394 $134–$1,168 $164
2025 $1,489 $424 $139–$1,306 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $3,746 44 payments
  2. Wright Medical Technology, Inc. $2,367 22 payments
  3. Smith+Nephew, Inc. $1,232 20 payments
  4. Bioventus LLC $1,000 22 payments
  5. Organogenesis Inc. $312 6 payments
  6. Osiris Therapeutics Inc. $290 4 payments
  7. Treace Medical Concepts, Inc. $230 1 payment
  8. Integra LifeSciences Corporation $218 4 payments
  9. Djo, LLC $144 2 payments
  10. Kerecis Limited $142 1 payment
  11. Other $74 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,914 119 payments
  2. Travel and Lodging $1,841 8 payments
Products named General payments · program years 2019–2025
  1. SALVATION $1,181 12 payments
  2. CITREFIX $1,026 11 payments
  3. PROSTEP $994 6 payments
  4. 7 X 23MM CITRELOCK IMPLANT $698 7 payments
  5. HOFFMANN $659 8 payments
  6. Stravix $650 7 payments
  7. ALLOWRAP $628 7 payments
  8. FLEXBAND $578 6 payments
  9. Exogen $546 13 payments
  10. VARIAX $521 5 payments
  11. Other $8,529 117 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

128

Median for Podiatry: 160

Drug cost

$12,875

Median for Podiatry: $2,368

Branded share of claims

27.3%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Santyl Collagenase Clostridium Hist. Brand 21 $10,151
Ciclopirox Generic 45 $2,056
Clotrimazole Generic 35 $386
Ammonium Lactate Generic 13 $216
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 14 $66

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 39 billing codes

Paid by Medicare

$80,059

Of which drugs: $3

Medicare patients

252

Average age 75

Services billed

1,168

129 women, 123 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 62%
Diabetes 59%
Ischemic heart disease 46%
Chronic kidney disease 35%
Heart failure 29%
Depression 26%
Atrial fibrillation 24%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 15 31 $3

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

127 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist, Foot & Ankle Surgery in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record